Cytokinetics Inc (NASDAQ: CYTK)’s stock price has increased by 2.71 compared to its previous closing price of 48.65. However, the company has seen a 4.41% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-30 that NEW YORK, Jan. 30, 2025 /PRNewswire/ — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Cytokinetics, Inc. (NASDAQ: CYTK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Is It Worth Investing in Cytokinetics Inc (NASDAQ: CYTK) Right Now?
Moreover, the 36-month beta value for CYTK is 0.83. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 7 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CYTK is 113.56M and currently, short sellers hold a 12.36% of that float. On January 31, 2025, CYTK’s average trading volume was 1.24M shares.
CYTK’s Market Performance
The stock of Cytokinetics Inc (CYTK) has seen a 4.41% increase in the past week, with a 5.51% rise in the past month, and a -4.38% fall in the past quarter. The volatility ratio for the week is 5.06%, and the volatility levels for the past 30 days are at 4.04% for CYTK. The simple moving average for the last 20 days is 4.42% for CYTK stock, with a simple moving average of -8.13% for the last 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Stifel repeating the rating for CYTK by listing it as a “Buy.” The predicted price for CYTK in the upcoming period, according to Stifel is $80 based on the research report published on January 22, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $80. The rating they have provided for CYTK stocks is “Outperform” according to the report published on November 08th, 2024.
Goldman gave a rating of “Neutral” to CYTK, setting the target price at $60 in the report published on August 13th of the previous year.
CYTK Trading at 2.10% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.55% of loss for the given period.
Volatility was left at 4.04%, however, over the last 30 days, the volatility rate increased by 5.06%, as shares surge +5.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.65% lower at present.
During the last 5 trading sessions, CYTK rose by +4.41%, which changed the moving average for the period of 200-days by -30.17% in comparison to the 20-day moving average, which settled at $47.85. In addition, Cytokinetics Inc saw 6.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 2,000 shares at the price of $45.92 back on Jan 21 ’25. After this action, Malik Fady Ibraham now owns 116,071 shares of Cytokinetics Inc, valued at $91,840 using the latest closing price.
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Inc, sale 2,000 shares at $49.32 during a trade that took place back on Jan 07 ’25, which means that Malik Fady Ibraham is holding 116,071 shares at $98,640 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -162.98 for the present operating margin
- -28.72 for the gross margin
The net margin for Cytokinetics Inc stands at -179.06. The total capital return value is set at -0.4.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at -56.76. The interest coverage ratio of the stock is -6.48.
Currently, EBITDA for the company is -456.68 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 2062.72. The receivables turnover for the company is 13.19for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.28.
Conclusion
To wrap up, the performance of Cytokinetics Inc (CYTK) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
